Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?

by · The Markets Daily

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $79.86, but opened at $71.64. Zealand Pharma A/S shares last traded at $71.64, with a volume of 200 shares traded.

Analyst Upgrades and Downgrades

ZLDPF has been the topic of a number of recent research reports. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday. Six analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Strong Buy”.

Read Our Latest Research Report on Zealand Pharma A/S

Zealand Pharma A/S Trading Down 9.0%

The company has a market cap of $5.09 billion, a price-to-earnings ratio of 5.15 and a beta of 0.72. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02. The business’s fifty day simple moving average is $76.65 and its two-hundred day simple moving average is $68.12.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.21. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. The business had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. On average, equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Recommended Stories